Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Italy.
Clin Exp Rheumatol. 2012 Nov-Dec;30(6):856-63. Epub 2012 Dec 17.
To evaluate disease activity patterns and flare occurrence in a cohort of systemic lupus erythematosus (SLE) patients.
Patients registered in our lupus Database, diagnosed with SLE between 1991 and 2004 and followed up quarterly from 2004 to 2010 were considered in the study. Disease activity patterns were defined using SLE Disease Activity Index-2000 (SLEDAI-2K), excluding serology, as follows: clinical quiescent disease (CQD), SLEDAI-2K=0 in the three annual visits; minimal disease activity (MDA), SLEDAI-2K=1 in one or more annual visits; chronic active disease (CAD), SLEDAI-2K≥2 in at least two annual visits; relapsing-remitting disease (RRD), SLEDAI-2K≥2 in one out of 3 annual visits. Flare was defined as an increase in SLEDAI-2K≥4 from the previous visit, according to SELENA-SLEDAI flare index.
One hundred and sixty-five patients fulfilled the inclusion criteria. During the 7 year follow-up, 109 (66%) patients experienced at least one period of active disease (CAD, RRD and MDA), whereas 56 patients (34%) had a persistent CQD. The mean±SD number of patients in each pattern per year was: CAD 52.4±5.8 (31.7%), RRD 16.1±6.8 (9.7%), MDA 9.7±1.7, (5.9%), CQD 87±10.5 (52.6%). Annual flare-rate was 0.19 flare per patient/year and mean±SD number of flares was higher in CAD compared with RRD patients (p<0.01). At the multivariate analysis positive anti-dsDNA antibodies, low C3 or C4, male sex, longer lag time between SLE onset and diagnosis, higher number of flares, and use of immunosuppressant were independently associated with active disease including CAD and RRD patterns.
Two-thirds of our patients developed at least one period of active disease during the 7-year follow-up despite tight monitoring and standard treatment.
评估系统性红斑狼疮(SLE)患者队列中的疾病活动模式和发作情况。
研究纳入了 1991 年至 2004 年间确诊为 SLE 并于 2004 年至 2010 年期间每季度接受随访的患者。使用 SLE 疾病活动指数-2000(SLEDAI-2K)评估疾病活动模式,排除血清学指标,具体定义如下:临床静止性疾病(CQD),三次年度随访中 SLEDAI-2K 均为 0;微小疾病活动(MDA),一次或多次年度随访中 SLEDAI-2K 为 1;慢性活动性疾病(CAD),至少两次年度随访中 SLEDAI-2K≥2;复发缓解性疾病(RRD),三次年度随访中一次出现 SLEDAI-2K≥2。根据 SELENA-SLEDAI 发作指数,发作定义为与前一次就诊相比 SLEDAI-2K 增加≥4。
165 名患者符合纳入标准。在 7 年的随访期间,109 名(66%)患者至少经历过一次活动期疾病(CAD、RRD 和 MDA),而 56 名(34%)患者则持续处于 CQD。每年每种模式的患者平均人数分别为:CAD 52.4±5.8(31.7%)、RRD 16.1±6.8(9.7%)、MDA 9.7±1.7(5.9%)、CQD 87±10.5(52.6%)。每年的发作率为 0.19 次/患者/年,CAD 患者的平均发作次数高于 RRD 患者(p<0.01)。多变量分析显示,抗 dsDNA 抗体阳性、C3 或 C4 水平低、男性、SLE 发病至确诊的时间间隔较长、发作次数较多以及免疫抑制剂的使用与包括 CAD 和 RRD 模式在内的活动性疾病独立相关。
尽管进行了严密监测和标准治疗,但在 7 年的随访期间,我们的患者中有三分之二至少经历了一次活动期疾病。